These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16138348)

  • 1. Treatment of refractory immune cytopenias in the 21st century--how safe is rituximab?
    Ravindranath Y
    Am J Hematol; 2005 Sep; 80(1):92-3. PubMed ID: 16138348
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of rituximab in cutaneous medicine.
    Scheinfeld N
    Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
    Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab: a B-cell depletion therapy for dermatologic disease.
    Prajapati V; Mydlarski PR
    Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic myeloid leukemia in the 21st century: biology and treatment].
    Chávez-González MA; Ayala-Sánchez M; Mayani H
    Rev Invest Clin; 2009; 61(3):221-32. PubMed ID: 19736811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab.
    von Bonin M; Oelschlägel U; Radke J; Stewart M; Ehninger G; Bornhauser M; Platzbecker U
    Transplantation; 2008 Sep; 86(6):875-9. PubMed ID: 18813113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.
    Kim JJ; Thrasher AJ; Jones AM; Davies EG; Cale CM
    Br J Haematol; 2007 Jul; 138(1):94-6. PubMed ID: 17498197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia.
    Qazilbash MH; Qu Z; Hosing C; Couriel D; Donato M; Giralt S; Champlin R
    Am J Hematol; 2005 Sep; 80(1):43-5. PubMed ID: 16138357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmacogenetics and tailored drug therapy].
    Nielsen FC; Borregaard N
    Ugeskr Laeger; 2009 Mar; 171(10):790-4. PubMed ID: 19265602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of biological response modifiers to enhance the action of Rituximab.
    Taylor RP
    Leuk Res; 2005 Jun; 29(6):599-600. PubMed ID: 15863194
    [No Abstract]   [Full Text] [Related]  

  • 13. Antituberculosis therapy and imatinib for chronic myeloid leukemia.
    Sorà F; De Matteis S; Di Mario A; Maiuro G; Laurenti L; Chiusolo P; Ardito F; Leone G; Sica S
    Clin Infect Dis; 2006 Nov; 43(9):1224. PubMed ID: 17029152
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of refractory pyoderma gangrenosum with intravenous immunoglobulin.
    de Zwaan SE; Iland HJ; Damian DL
    Australas J Dermatol; 2009 Feb; 50(1):56-9. PubMed ID: 19178495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
    Bussone G; Ribeiro E; Dechartres A; Viallard JF; Bonnotte B; Fain O; Godeau B; Michel M
    Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: applications in dermatology.
    Fatourechi MM; el-Azhary RA; Gibson LE
    Int J Dermatol; 2006 Oct; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
    Uchiyama M; Ikeda T
    Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
    Kuwana M; Iki S; Urabe A
    Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Lichtman MA
    Oncologist; 2008 Jun; 13(6):645-54. PubMed ID: 18586919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Delayed response to rituximab of cold agglutinin haemolytic disease].
    Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
    An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.